JSM 6427

Drug Profile

JSM 6427

Alternative Names: JSM-6427

Latest Information Update: 04 Mar 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jerini Ophthalmic
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Integrin alpha 5 beta 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Age-related macular degeneration; Proliferative vitreoretinopathy

Most Recent Events

  • 04 Mar 2011 Development discontinued for Age-related macular degeneration during 2010
  • 10 Apr 2008 Jerini Ophthalmic signs an exclusive licensing and development agreement with PR Pharmaceuticals to develop sustained-release formulations, including JSM 6427 for the treatment of age-related macular degeneration
  • 07 Dec 2007 Jerini Ophthalmic enters into a research collaboration agreement with University College London Institute of Ophthalmology for the development of JSM 6427 in age-related macular degeneration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top